Literature DB >> 179708

Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide and its metabolites on Novikoff hepatoma cells.

D D Beal, J L Skibba, K K Whitnable, G T Bryan.   

Abstract

Studies were undertaken to determine the effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) and its metabolites on the growth and macromolecular synthesis of Novikoff hepatoma cells in culture. DTIC (3.0 mM) in light decreased the viable cell count by 90% within 96 hr. DTIC protected from light, 2-azahypoxanthine, dimethylamine, and 5-aminoimidazole-4-carboxamide, all at 3.0 mM, reduced the rate of cellular proliferation. 5-Diazoimidazole-4-carboxamide (1.0 mM) and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (3.0 mM) decreased the viable cell count by 99%. Effects on macromolecular synthesis were determined by the rate of incorporation of the appropriate 3H-labeled precursor. Results after 6 hr are given as percentage of controls. DTIC (1.0 mM) in light inhibited DNA (8%), RNA (41%), and protein (63%) synthesis. DTIC (1.0 mM) protected from light inhibited DNA (12%) and RNA (57%) synthesis. 5-Diazoimidazole-4-carboxamide (0.1 mM) inhibited DNA (1%), RNA (9%), and protein (1%) synthesis. 5-(3-Methyl-1-triazeno)imidazole-4-carboxamide (1.0 mM) inhibited DNA (72%) and protein (65%) synthesis but stimulated RNA (127%) synthesis. 2-Azahypoxanthine (1.0 mM) inhibited DNA (43%), RNA 82%) and protein (28%) synthesis. 5-Aminoimidazole-4-carboxamide (3.0 mM) stimulated DNA (354%) and RNA (266%) synthesis. These data show that DTIC is able to generate several toxic metabolites that may be responsible for its biological effects.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 179708

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Pharmacokinetics of dacarbazine (DTIC) in pregnancy.

Authors:  Ira Kantrowitz-Gordon; Karen Hays; Olumide Kayode; Aditya R Kumar; Henry G Kaplan; Joel M Reid; Stephanie L Safgren; Matthew M Ames; Thomas R Easterling; Mary F Hebert
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-05       Impact factor: 3.333

2.  Pharmacologic studies of anticancer drugs with the human tumor stem cell assay.

Authors:  D S Alberts; S E Salmon; H S Chen; T E Moon; L Young; E A Surwit
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Clinical pharmacokinetics of high-dose DTIC.

Authors:  J M Buesa; E Urréchaga
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  DTIC and CPZ cytotoxicities on established human melanocyte cell lines.

Authors:  C Aubert; F Rouge
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

5.  The antitumour agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) inhibits rat liver cAMP phosphodiesterase and amplifies hormone effects in hepatocytes and hepatoma cells.

Authors:  P G Larsson; F Haffner; G O Brłnstad; T Christoffersen
Journal:  Br J Cancer       Date:  1979-11       Impact factor: 7.640

6.  Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells.

Authors:  Diana Salvador; Verónica Bastos; Helena Oliveira
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

Review 7.  Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.

Authors:  Hannah Strobel; Tim Baisch; Rahel Fitzel; Katharina Schilberg; Markus D Siegelin; Georg Karpel-Massler; Klaus-Michael Debatin; Mike-Andrew Westhoff
Journal:  Biomedicines       Date:  2019-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.